Study: Evolocumab Shows a Higher Reduction in LDL-C Than Alirocumab -

At week 4, there was about a 61.6% decrease for individuals with hypercholesterolemia who do not attain low-density lipoprotein cholesterol and/or are intolerant to other lipid-lowering drugs.